Item 8.01. Other Events.
On November 1, 2017, AveXis, Inc. (the Registrant) issued a press release to report data as of August 7, 2017 from the Registrants Phase 1 clinical trial of AVXS-101 in spinal muscular atrophy Type 1. These data were published in the New England Journal of Medicine in a paper titled Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.